Date: 2014-10-09
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Abbvie (USA - IL)
Product: veliparib (ABT-888)
Action
mechanism: poly ADP ribose polymerase PARP inhibitor/PARP inhibitor. Veliparib is an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor being evaluated in multiple tumor types. PARP is a naturally-occurring enzyme in the body that repairs damage to DNA, and in certain types of cancers, repairs cancer cells. Discovered by AbbVie researchers, veliparib is being developed to help prevent DNA repair in cancer cells and increase the effectiveness of common DNA-damaging therapies like chemotherapy or radiation.
Veliparib is currently being studied in more than a dozen cancers and tumor types, including Phase 3 studies in non-small cell lung cancer and breast cancer.
Disease: non-squamous non-small cell lung cancer
Therapeutic area: Cancer - Oncology
Country: Argentina, Australia, Canada, Czech Republic, Denmark, Finland, Germany, Hungary, Israel, Japan, Republic of Korea, The Netherlands, New Zealand, Russian Federation, South Africa, Spain, Taiwan, Turkey, UK, USA, France
Trial
details: This 2-arm, Phase 3 study to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in current or former smokers who are receiving their first cytotoxic therapy for metastatic or advanced non-squamous non-small cell lung cancer. ( NCT02264990)
Latest
news: * On October 9, 2014, a new Phase 3 trial with veliparib, an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor was published on ClinicalTrials.gov " Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers".
